ABBVIE INC

AbbVie’s July 2026 ex‑dividend and Skyrizi‑driven $300 target show a resilient dividend strategy amid a brief price dip, yet drug‑pricing policy shifts still shape future gains.

AbbVie’s Apogee deal shifts focus from Humira to a diversified pipeline, targeting immunology, oncology, and neurology breakthroughs.

AbbVie’s EPCORE DLBCL‑4 trial shows a 60% reduction in progression risk with epcoritamab + lenalidomide, boosting investor confidence and expanding its oncology and dermatology portfolio amid regulatory wins and global collaborations.

AbbVie’s $10.9B acquisition of Apogee and FDA approval of Skyrizi for pediatric psoriasis signal a robust pipeline expansion and new revenue streams amid biosimilar competition.

AbbVie’s steady dividend, Crohn’s disease expansion plans, and $1.4B manufacturing investment reveal a robust strategy that balances shareholder returns with future growth opportunities.

AbbVie’s stock faces a bearish trend, but strong dividends, a 10% sales growth, and a $650 M partnership with RemeGen hint at resilience – can investors ride the dip or risk a slide?

AbbVie partners with MLB to boost its oncology campaign, using sports reach to spread cancer awareness and potentially lift its undervalued stock.

AbbVie’s stock dips below its 50‑day SMA amid rising competition, as J&J’s new oral psoriasis pill threatens Skyrizi’s market share, prompting investors to rethink the biotech’s high valuation.

AbbVie 2026 outlook: high‑cap pharma leader with $380 m manufacturing expansion, AI‑driven pipeline, and “Outperform” analyst support—investors weigh robust growth vs. lofty PE.

AbbVie’s bold moves—FDA‑approved blood cancer combo, oncology breakthroughs, and growing women’s health focus—show how the $397B biotech leader keeps leading the pharma frontier while delivering dividends and investor value.